SCHEMBL6984529

SCHEMBL6984529

O=C1CC=Nc2c1c(O)cc1cccnc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.41
L3MBTL1 Q9Y468 9/20 0.41
NPC1 O15118 6/20 0.41
RAB9A P51151 5/20 0.41
MAPT P10636 1/20 0.40
PKM P14618 1/20 0.40
NFKB1 P19838 1/20 0.40
HTT P42858 1/20 0.40
CASP6 P55212 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
DAO P14920 1/20 0.39
COMT P21964 2/20 0.39
MMP2 P08253 1/20 0.39
CHRM1 P11229 1/20 0.39
TSHR P16473 1/20 0.39
ADRA1A P35348 1/20 0.39
METAP2 P50579 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL963924 0.74 LMNA (0.50) KDM4EL3MBTL1MAPTNFKB1HTT
SCHEMBL967454 0.71 L3MBTL1 (0.39) KDM4EL3MBTL1NPC1RAB9AMAPT
SCHEMBL27847333 0.71 LMNA (0.46) KDM4EL3MBTL1MAPTNFKB1HTT
SCHEMBL6978820 0.70 KDM4E (0.37) KDM4EL3MBTL1NPC1RAB9AMAPT
SCHEMBL32664880 0.67 CCR1 (0.36) KDM4EL3MBTL1NPC1RAB9AMAPT
SCHEMBL170139 0.63 ALDH1A1 (0.59) KDM4EL3MBTL1NPC1RAB9AMAPT
SCHEMBL169518 0.63 L3MBTL1 (0.61) KDM4EL3MBTL1NPC1RAB9AMAPT
SCHEMBL29683521 0.63 L3MBTL1 (0.61) KDM4EL3MBTL1NPC1RAB9AMAPT
SCHEMBL6978190 0.63 MEN1 (0.31) MAPTLMNA
SCHEMBL364531 0.62 KDM4E (0.57) KDM4EL3MBTL1NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1027351-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 2003-12-03 EP disclosed
US-20010001101-A1 Phenanthroline derivatives ZENECA LIMITED 2001-05-10 US disclosed
US-6200974-B1 FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT ZENECA LIMITED (GB) 2001-03-13 US disclosed
EP-1027351-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 2000-08-16 EP disclosed
US-5916898-A ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS ZENECA LIMITED (GB) 1999-06-29 US disclosed
WO-1999021860-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010001101-A1 Phenanthroline derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 KDM4E 162/4885L3MBTL1 2168/4885NPC1 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.